Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Darbepoetin_alfa> ?p ?o. }
Showing items 1 to 73 of
73
with 100 items per page.
- Darbepoetin_alfa abstract "Darbepoetin alfa (rINN) /dɑrbəˈpɔɪtɨn/ is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy. Darbepoetin is marketed by Amgen under the trade name Aranesp.The drug was approved in September 2001 by the Food and Drug Administration for treatment of anemia in patients with chronic renal failure by intravenous or subcutaneous injection. In June 2001, it had been approved by the European Medicines Agency for this indication as well as the treatment of anemia in cancer patients undergoing chemotherapy.Dr. Reddy's Laboratories launched darbepoetin alfa in India under the brand name ‘Cresp’ in August 2010. This is the world’s first generic darbepoetin alfa. Cresp has been approved in India.Darbepoetin is produced by recombinant DNA technology in modified Chinese hamster ovary cells.[citation needed] It differs from endogenous erythropoietin (EPO) by containing two more N-linked oligosaccharide chains. It is an erythropoiesis-stimulating 165-amino acid protein.Like EPO, its use increases the risk of cardiovascular problems, including cardiac arrest, arrhythmia, hypertension and hypertensive encephalopathy, congestive heart failure, vascular thrombosis or ischemia, myocardial infarction, edema, and stroke. It can also increase risk of seizures. A recent study has extended these findings to treatment of patients exhibiting cancer-related anemia (distinct from anemia resulting from chemotherapy). Pre-existing untreated hypertension is a contra-indication for darbepoetin, as well as some hematologic diseases. Other reported adverse reactions include hypotension, fever, chest pains, nausea and myalgia.Like EPO, it has the potential to be abused by athletes seeking a competitive advantage. Its use during the 2002 Winter Olympic Games to improve performance led to the disqualification of cross-country skiers Larisa Lazutina and Olga Danilova of Russia and Johann Mühlegg of Spain from their final races.".
- Darbepoetin_alfa atcPrefix "B03".
- Darbepoetin_alfa atcSuffix "XA02".
- Darbepoetin_alfa casNumber "11096-26-7".
- Darbepoetin_alfa drugbank "DB00012".
- Darbepoetin_alfa fdaUniiCode "15UQ94PT4P".
- Darbepoetin_alfa wikiPageID "40592".
- Darbepoetin_alfa wikiPageRevisionID "604960988".
- Darbepoetin_alfa atcPrefix "B03".
- Darbepoetin_alfa atcSuffix "XA02".
- Darbepoetin_alfa c "815".
- Darbepoetin_alfa casNumber "11096".
- Darbepoetin_alfa chemspiderid "NA".
- Darbepoetin_alfa drugbank "DB00012".
- Darbepoetin_alfa h "1317".
- Darbepoetin_alfa hasPhotoCollection Darbepoetin_alfa.
- Darbepoetin_alfa legalAu "S4".
- Darbepoetin_alfa licenceEu "Aranesp".
- Darbepoetin_alfa licenceUs "Darbepoetin_alfa".
- Darbepoetin_alfa medlineplus "a604022".
- Darbepoetin_alfa molecularWeight "18396.1".
- Darbepoetin_alfa n "233".
- Darbepoetin_alfa o "241".
- Darbepoetin_alfa pregnancyAu "B3".
- Darbepoetin_alfa s "5".
- Darbepoetin_alfa unii "15".
- Darbepoetin_alfa verifiedfields "changed".
- Darbepoetin_alfa verifiedrevid "460773610".
- Darbepoetin_alfa subject Category:Antianemic_preparations.
- Darbepoetin_alfa subject Category:Erythropoiesis-stimulating_agents.
- Darbepoetin_alfa subject Category:Growth_factors.
- Darbepoetin_alfa type Abstraction100002137.
- Darbepoetin_alfa type Act100030358.
- Darbepoetin_alfa type Activity100407535.
- Darbepoetin_alfa type AntianemicPreparations.
- Darbepoetin_alfa type Chemical114806838.
- Darbepoetin_alfa type Compound114818238.
- Darbepoetin_alfa type Event100029378.
- Darbepoetin_alfa type GrowthFactor114734348.
- Darbepoetin_alfa type GrowthFactors.
- Darbepoetin_alfa type Macromolecule114944888.
- Darbepoetin_alfa type Material114580897.
- Darbepoetin_alfa type Matter100020827.
- Darbepoetin_alfa type Molecule114682133.
- Darbepoetin_alfa type OrganicCompound114727670.
- Darbepoetin_alfa type Part113809207.
- Darbepoetin_alfa type PhysicalEntity100001930.
- Darbepoetin_alfa type Preparation101143040.
- Darbepoetin_alfa type Protein114728724.
- Darbepoetin_alfa type PsychologicalFeature100023100.
- Darbepoetin_alfa type Relation100031921.
- Darbepoetin_alfa type Substance100019613.
- Darbepoetin_alfa type Thing100002452.
- Darbepoetin_alfa type Unit109465459.
- Darbepoetin_alfa type YagoPermanentlyLocatedEntity.
- Darbepoetin_alfa type Drug.
- Darbepoetin_alfa type DrugProduct.
- Darbepoetin_alfa type FunctionalSubstance.
- Darbepoetin_alfa comment "Darbepoetin alfa (rINN) /dɑrbəˈpɔɪtɨn/ is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy. Darbepoetin is marketed by Amgen under the trade name Aranesp.The drug was approved in September 2001 by the Food and Drug Administration for treatment of anemia in patients with chronic renal failure by intravenous or subcutaneous injection.".
- Darbepoetin_alfa label "Aranesp".
- Darbepoetin_alfa label "Darbepoetin alfa".
- Darbepoetin_alfa label "Darbepoetina alfa".
- Darbepoetin_alfa label "Darbepoetina alfa".
- Darbepoetin_alfa sameAs Darbepoetina_alfa.
- Darbepoetin_alfa sameAs Aranesp.
- Darbepoetin_alfa sameAs Darbepoetina_alfa.
- Darbepoetin_alfa sameAs m.0b3nw.
- Darbepoetin_alfa sameAs Q2178381.
- Darbepoetin_alfa sameAs Q2178381.
- Darbepoetin_alfa sameAs DB00012.
- Darbepoetin_alfa sameAs Darbepoetin_alfa.
- Darbepoetin_alfa wasDerivedFrom Darbepoetin_alfa?oldid=604960988.
- Darbepoetin_alfa isPrimaryTopicOf Darbepoetin_alfa.